Latest news with #UFPTechnologies
Globe and Mail
5 days ago
- Business
- Globe and Mail
UFP Technologies, Inc. to Present and Host 1x1 Investor Meetings at the Goldman Sachs 46th Annual Global Healthcare Conference
NEWBURYPORT, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- UFP Technologies, Inc. (Nasdaq: UFPT), today announced that Jeffrey Bailly, Chairman and CEO, and Ron Lataille, Sr. Vice President & CFO, will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025. UFP's fireside chat is scheduled to begin at 11:20 AM ET. About UFP Technologies, Inc. UFP Technologies is a designer and custom manufacturer of comprehensive solutions for medical devices, sterile packaging, and other highly engineered custom products. UFP is an important link in the medical device supply chain and a valued outsourcing partner to many of the top medical device manufacturers in the world. The Company's single-use and single-patient devices and components are used in a wide range of medical devices and packaging for minimally invasive surgery, infection prevention, wound care, wearables, orthopedic soft goods, and orthopedic implants. Contact:
Yahoo
26-05-2025
- Business
- Yahoo
Life Sciences Tools & Services Stocks Q1 Recap: Benchmarking Illumina (NASDAQ:ILMN)
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let's have a look at Illumina (NASDAQ:ILMN) and its peers. The life sciences tools and services sector supports the research, development, and commercialization of biotechnology and pharmaceutical products. These companies offer a broad range of tools, from lab consumables and testing equipment to data analytics platforms and clinical trial support. There is recurring revenue potential from long-term contracts, high margins from specialized products, and the growing demand for precision medicine and data-driven insights. However, challenges include dependence on research and development budgets from large pharmaceutical companies and the boom and bust nature of smaller biotech companies. Looking forward, the life sciences tools and services sector is expected to benefit from strong tailwinds, including advancements in genomics and the rising focus on personalized medicine. Ongoing adoption of artificial intelligence in research and drug discovery, along with the growing need for regulatory compliance and data analytics, should provide longer-term demand support. However, headwinds such as the uncertainty around healthcare and research funding as well as pricing pressures from cost-conscious customers may feed into uncertainty in the sector. The 20 life sciences tools & services stocks we track reported a strong Q1. As a group, revenues beat analysts' consensus estimates by 3.3% while next quarter's revenue guidance was 0.9% above. While some life sciences tools & services stocks have fared somewhat better than others, they have collectively declined. On average, share prices are down 3.7% since the latest earnings results. Pioneering the ability to read the human genome at unprecedented speed and affordability, Illumina (NASDAQ:ILMN) develops and sells advanced DNA sequencing and microarray technologies that allow researchers and clinicians to analyze genetic variations and functions. Illumina reported revenues of $1.04 billion, down 1.4% year on year. This print exceeded analysts' expectations by 0.5%. Despite the top-line beat, it was still a mixed quarter for the company with an impressive beat of analysts' EPS guidance for next quarter estimates. The stock is up 1.8% since reporting and currently trades at $81. Is now the time to buy Illumina? Access our full analysis of the earnings results here, it's free. With expertise dating back to 1963 in specialized materials and precision manufacturing, UFP Technologies (NASDAQ:UFPT) designs and manufactures custom solutions for medical devices, sterile packaging, and other highly engineered products for healthcare and industrial applications. UFP Technologies reported revenues of $148.1 million, up 41.1% year on year, outperforming analysts' expectations by 5.9%. The business had an incredible quarter with an impressive beat of analysts' EPS estimates. UFP Technologies delivered the fastest revenue growth among its peers. The market seems happy with the results as the stock is up 19.5% since reporting. It currently trades at $235.61. Is now the time to buy UFP Technologies? Access our full analysis of the earnings results here, it's free. With roots dating back to 1904 and embedded in virtually every stage of scientific research and production, Avantor (NYSE:AVTR) provides mission-critical products, materials, and services to customers in biopharma, healthcare, education, and advanced technology industries. Avantor reported revenues of $1.58 billion, down 5.9% year on year, falling short of analysts' expectations by 1.6%. It was a softer quarter as it posted a miss of analysts' organic revenue estimates. Avantor delivered the weakest performance against analyst estimates and slowest revenue growth in the group. As expected, the stock is down 17.6% since the results and currently trades at $12.75. Read our full analysis of Avantor's results here. Pioneering what scientists call "HiFi long-read sequencing," recognized as Nature Methods' method of the year for 2022, Pacific Biosciences (NASDAQ:PACB) develops advanced DNA sequencing systems that enable scientists and researchers to analyze genomes with unprecedented accuracy and completeness. PacBio reported revenues of $37.15 million, down 4.3% year on year. This number surpassed analysts' expectations by 5.2%. Overall, it was a stunning quarter as it also produced an impressive beat of analysts' EPS estimates. The stock is down 22.7% since reporting and currently trades at $0.92. Read our full, actionable report on PacBio here, it's free. Serving as the guardian of some of medicine's most valuable materials, Azenta (NASDAQ:AZTA) provides biological sample management, storage, and genomic services that help pharmaceutical and biotechnology companies preserve and analyze critical research materials. Azenta reported revenues of $143.4 million, up 5.2% year on year. This print topped analysts' expectations by 2%. More broadly, it was a slower quarter as it produced a significant miss of analysts' EPS estimates. The stock is up 7.2% since reporting and currently trades at $27.26. Read our full, actionable report on Azenta here, it's free. Thanks to the Fed's rate hikes in 2022 and 2023, inflation has been on a steady path downward, easing back toward that 2% sweet spot. Fortunately (miraculously to some), all this tightening didn't send the economy tumbling into a recession, so here we are, cautiously celebrating a soft landing. The cherry on top? Recent rate cuts (half a point in September 2024, a quarter in November) have propped up markets, especially after Trump's November win lit a fire under major indices and sent them to all-time highs. However, there's still plenty to ponder — tariffs, corporate tax cuts, and what 2025 might hold for the economy. Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Quality Compounder Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Join Paid Stock Investor Research Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20-05-2025
- Business
- Yahoo
UFPT Q1 Earnings Call: Medical Segment Growth and Strategic Expansion Drive Outperformance
Medical products company UFP Technologies (NASDAQ:UFPT) announced better-than-expected revenue in Q1 CY2025, with sales up 41.1% year on year to $148.1 million. Its non-GAAP profit of $2.47 per share was 22.9% above analysts' consensus estimates. Is now the time to buy UFPT? Find out in our full research report (it's free). Revenue: $148.1 million vs analyst estimates of $139.9 million (41.1% year-on-year growth, 5.9% beat) Adjusted EPS: $2.47 vs analyst estimates of $2.01 (22.9% beat) Adjusted EBITDA: $30.24 million vs analyst estimates of $28.26 million (20.4% margin, 7% beat) Operating Margin: 15.8%, in line with the same quarter last year Market Capitalization: $1.95 billion UFP Technologies' first quarter was shaped by outsized growth in its medical business segments, particularly in safe patient handling, interventional, and infection prevention, all of which benefited from a combination of new account wins and increased overall market demand. Management attributed much of this growth to successful integration of recent acquisitions, notably AJR, which delivered significant revenue gains and expanded UFP Technologies' exposure to high-growth medical categories. CEO Jeff Bailly stated, 'The scale and rapid growth of our safe patient handling business are strategically important as it adds a new high-growth market segment for our medical portfolio and further diversifies our company.' Looking ahead, management emphasized continued investment in expanding manufacturing capabilities, particularly in the Dominican Republic, as well as progress on new product launches within robotic surgery. While leadership expects robotic surgery growth to be modest following an inventory build in 2024, they highlighted the potential for new program launches later this year and ongoing discussions to support broader needs for key customers. CFO Ron Lataille noted that tariff-related risks remain limited, with most potential costs expected to be passed on, though some uncertainty may persist in customer demand and material sourcing. First quarter results were mainly driven by sharp growth in medical markets and effective integration of new acquisitions. Management discussed operational efficiency, competitive positioning, and expansion initiatives as drivers of the results. Safe Patient Handling Expansion: The safe patient handling segment became UFP Technologies' second largest business, growing rapidly due to both new market share wins and increased demand. This was enabled by the AJR acquisition and exclusive manufacturing agreements with key customers. Diversified Medtech Growth: Significant gains were seen in interventional, surgical infection prevention, orthopedics, and advanced wound care, each growing over 25% year over year, as pandemic-related inventory destocking at customers subsided. Acquisition Integration: Management credited recent acquisitions, especially AJR, for accelerating growth. Acquisitions have outperformed prior run rates, with cross-selling and expanded capabilities allowing acquired companies to grow faster than they would have independently. Robotic Surgery Transition: The robotic surgery segment experienced a year-over-year decline following an inventory build, with management guiding for only modest growth in 2025. However, two new programs are set to launch later this year, expected to provide incremental revenue in 2026. Dominican Republic Facility Investment: Major investments in manufacturing and R&D capacity in the Dominican Republic position the company to support exclusive customer contracts and improve cost efficiency. These moves are considered a key competitive advantage for future growth. Management's outlook for the remainder of the year centers on sustained momentum in medical end markets, continued integration of recent acquisitions, and strategic manufacturing expansion, while monitoring tariff implications and customer demand patterns. Manufacturing Expansion: Ongoing buildout in the Dominican Republic is expected to support capacity for new and existing contracts, enabling cost efficiencies and increasing the scope for future business. New Product Launches: The ramp of new robotic surgery programs in the second half of the year could shift growth drivers, with meaningful contributions anticipated in 2026. Tariff and Supply Chain Risk: While management expects to pass most tariff costs to customers, they acknowledge potential uncertainties in demand and inflationary effects from global sourcing. Jaeson Schmidt (Lake Street): Asked whether anticipated 'modest' growth in robotic surgery applies to both the largest customer and the overall segment. Management confirmed low single-digit growth is expected for both, supported by new programs that will add incremental gains. Brett Fishbin (KeyBanc): Inquired about growth acceleration in medical segments outside of robotics, particularly infection prevention and acquisitions. Management cited destocking headwinds easing and cross-selling from acquisitions as drivers. Justin Ages (CJS): Questioned whether tariffs might impact UFP Technologies differently compared to competitors. Management noted competitors with Chinese manufacturing face greater headwinds, while the company's U.S. and Dominican Republic base offers a relative advantage. Andrew Cooper (Raymond James): Queried about the impact of price reductions in new safe patient handling contracts and whether operating profit margins would be maintained. Management expects margin expansion despite lower revenue per unit, driven by improved efficiency and market growth. Andrew Cooper (Raymond James): Asked about long-term manufacturing footprint strategy and potential expansion into Europe or Asia. Management indicated continued focus on the Dominican Republic, with the possibility of expanding to Asia-Pacific through joint ventures to support client needs. In the coming quarters, the StockStory team will focus on (1) the pace and success of manufacturing expansion in the Dominican Republic and the associated operational efficiencies, (2) the performance and integration of recent acquisitions, especially in safe patient handling, and (3) progress on new product launches in the robotic surgery segment. We will also monitor tariff developments and any impact on customer demand and raw material costs. UFP Technologies currently trades at a forward P/E ratio of 27.8×. In the wake of earnings, is it a buy or sell? Find out in our free research report. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 176% over the last five years. Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
Yahoo
06-05-2025
- Business
- Yahoo
UFP Technologies (NASDAQ:UFPT) Reports Upbeat Q1, Stock Soars
Medical products company UFP Technologies (NASDAQ:UFPT) reported Q1 CY2025 results topping the market's revenue expectations , with sales up 41.1% year on year to $148.1 million. Its non-GAAP profit of $2.47 per share was 22.9% above analysts' consensus estimates. Is now the time to buy UFP Technologies? Find out in our full research report. UFP Technologies (UFPT) Q1 CY2025 Highlights: Revenue: $148.1 million vs analyst estimates of $139.9 million (41.1% year-on-year growth, 5.9% beat) Adjusted EPS: $2.47 vs analyst estimates of $2.01 (22.9% beat) Adjusted EBITDA: $30.24 million vs analyst estimates of $28.26 million (20.4% margin, 7% beat) Operating Margin: 15.6%, in line with the same quarter last year Market Capitalization: $1.52 billion 'I am very pleased with our first quarter results and continued progress on a number of key strategic fronts,' said R. Jeffrey Bailly, Chairman & CEO. Company Overview With expertise dating back to 1963 in specialized materials and precision manufacturing, UFP Technologies (NASDAQ:UFPT) designs and manufactures custom solutions for medical devices, sterile packaging, and other highly engineered products for healthcare and industrial applications. Sales Growth A company's long-term sales performance is one signal of its overall quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, UFP Technologies grew its sales at an excellent 24.2% compounded annual growth rate. Its growth beat the average healthcare company and shows its offerings resonate with customers. UFP Technologies Quarterly Revenue Long-term growth is the most important, but within healthcare, a half-decade historical view may miss new innovations or demand cycles. UFP Technologies's annualized revenue growth of 20% over the last two years is below its five-year trend, but we still think the results suggest healthy demand. UFP Technologies Year-On-Year Revenue Growth This quarter, UFP Technologies reported magnificent year-on-year revenue growth of 41.1%, and its $148.1 million of revenue beat Wall Street's estimates by 5.9%. Looking ahead, sell-side analysts expect revenue to grow 9.1% over the next 12 months, a deceleration versus the last two years. Still, this projection is admirable and implies the market is baking in success for its products and services. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories.
Washington Post
06-05-2025
- Business
- Washington Post
UFP: Q1 Earnings Snapshot
NEWBURYPORT, Mass. — NEWBURYPORT, Mass. — UFP Technologies Inc. (UFPT) on Tuesday reported earnings of $17.2 million in its first quarter. The Newburyport, Massachusetts-based company said it had net income of $2.21 per share. Earnings, adjusted for one-time gains and costs, came to $2.47 per share.
